Skip to main content

Table 1 Patient characteristics at study onset

From: The pain trajectory of juvenile idiopathic arthritis (JIA): translating from adolescent patient report to behavioural sensitivity in a juvenile animal model

 

All patients

Trajectory:

Statistical analysis

Low pain

Variable pain

High pain

F value/Chi-Square

P value

No. of patients

97

45 (46.4%)

30 (30.9%)

22 (22.7%)

  

 Age at JIA onset

9.62 (4.86)

9.51 (4.71)

9.96 (4.88)

9.40 (5.31)

0.11

0.90

 Age at study onset

16.40 (1.21)

16.19 (1.18)

16.46 (1.16)

16.76 (1.31)

1.67

0.19

 Years since JIA onset

6.78 (5.17)

6.68 (4.97)

6.49 (5.33)

7.36 (5.55)

0.19

0.83

Sex:

    

8.05

0.018

 Female

55 (56.7%)

24 (53.3%)

13 (43.3%)

18 (81.8%)

  

 Male

42 (43.3%)

21 (46.7%)

17 (56.7%)

4 (18.2%)

  

Weeks between:

 Visit 1 and 2

24.12 (4.11)

24.24 (4.16)

24.30 (4.50)

23.64 (3.55)

0.20

0.82

 Visit 1 and 3

49.11 (5.74)

49.27 (4.92)

48.63 (6.91)

49.45 (5.77)

0.16

0.86

JIA subtype:

    

11.77

0.067

 Polyarticular course

54 (55.7%)

21 (46.7%)

16 (53.3%)

17 (77.3%)

  

 Oligoarticular

6 (6.2%)

4 (8.9%)

1 (3.3%)

1 (4.5%)

  

 Enthesitis Related

32 (33.0%)

15 (33.3%)

13 (43.3%)

4 (18.2%)

  

 Systemic

5 (5.2%)

5 (11.1%)

0 (0.0%)

0 (0.0%)

  

JIA activity markers:

 PGA (cm)

2.40 (2.52)

1.40 (2.11)

3.11 (2.73)

3.47 (2.31)

7.64

0.001

 No. of active joints

0 (0–2)

0 (0–1)

1 (0–1)

0 (0–2)

2.06

0.13

Medications:

 No. taking DMARDs

67 (69.1%)

27 (60.0%)

22 (73.3%)

18 (81.8%)

3.66

0.16

 No. taking Biologics

40 (41.2%)

18 (40.0%)

12 (40.0%)

10 (45.5%)

0.21

0.90

 No. taking Steroids

16 (16.5%)

4 (8.9%)

7 (23.3%)

5 (22.7%)

3.53

0.17

  1. Data is presented as mean (standard deviation) for continuous data, number (% of patients with trajectory type) for categorical data or median (interquartile range) for discrete data (e.g. joint count). Comparisons between trajectories which reach significance (p < 0.05) are indicated in bold. PGA = Physician global assessment VAS. DMARDs = Disease-modifying antirheumatic drugs